14hon MSN
Euronews Tech Talks: The podcast unravelling the big questions shaping Europe's digital landscape
Euronews Tech Talks goes beyond discussions to explore the impact of new technologies on our lives. View on euronews ...
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 13, 2026, the company granted (i) non-statutory stock options to purchase 9,600 shares of the company’s common stock to two newly hired ...
All attention is focused on Wednesday, February 25, when Schrodinger is scheduled to release its fourth-quarter and full-year 2025 financial figures after the U.S. market closes. The report will be ...
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software ...
Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February ...
Schrodinger Inc’s stock reached a 52-week low, hitting $15.97, marking a significant downturn for the company. According to InvestingPro data, the stock is currently trading just 1% above its 52-week ...
Jan 9 (Reuters) – Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major’s AI-based platform, TuneLab, on its drug designing software. Integration of Lilly’s ...
Schrödinger, Inc. (NASDAQ:SDGR) is one of the best healthcare AI stocks to buy now. On December 15, BofA Securities upgraded Schrödinger, Inc. (NASDAQ:SDGR) from Neutral to Buy, with a $24 price ...
Q3 revenue jumped 54% as software and drug discovery sales impressed, though the company trimmed guidance for software growth next year. Schrödinger posted third-quarter revenue of $54.3 million, ...
Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. Stearoyl-CoA desaturase (SCD) is a lipogenic enzyme involved in ...
Alzheimer’s disease is a devastating neurodegenerative disorder characterized by memory loss and cognitive decline. New AD treatments are essential, and drug repositioning is a promising approach. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results